The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
“This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.
- “This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME,” said Rick Eiswirth, President and Chief Executive Officer of Alimera.
- We look forward to the publication of Final Guidance shortly.”
NICE is recommending on label access to ILUVIEN as an option for treating visual impairment caused by chronic DME in phakic eyes. - NHS England has agreed with the Integrated Care Boards (ICB’s) to provide funding to implement this guidance 30 days after publication.
- NHS Wales will usually fund within 2 months of the final draft guidance.